Cargando…
IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
PURPOSE: The IGF and mTOR-pathways are considered as potential targets for therapy in patients with adrenocortical carcinoma (ACC). This study aims to describe the IGF pathway in ACC and to explore the response to the combined treatment with the IGF1R/IR inhibitor linsitinib, and mTOR inhibitors (si...
Autores principales: | De Martino, Maria Cristina, van Koetsveld, Peter M., Feelders, Richard A., de Herder, Wouter W., Dogan, Fadime, Janssen, Joseph A. M. J. L., Hofste op Bruinink, Davine, Pivonello, Claudia, Waaijers, A. Marlijn, Colao, Annamaria, de Krijger, Ronald R., Pivonello, Rosario, Hofland, Leo J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551351/ https://www.ncbi.nlm.nih.gov/pubmed/30838516 http://dx.doi.org/10.1007/s12020-019-01869-1 |
Ejemplares similares
-
The role of mTOR pathway as target for treatment in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019) -
The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma
por: Pivonello, Claudia, et al.
Publicado: (2016) -
Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma
por: Negri, Mariarosaria, et al.
Publicado: (2022) -
Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
por: Vandamme, Timon, et al.
Publicado: (2016) -
mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)